Patents by Inventor Alain Moussy

Alain Moussy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of tyrosine kinase inhibitors for treating inflammatory diseases
    Patent number: 7741335
    Abstract: The present invention relates to a method for treating inflammatory diseases such as rheumatoid arthritis (RA), comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 22, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Jean Pierre Kinet
  • Potent, selective and non toxic c-kit inhibitors
    Patent number: 7727731
    Abstract: The present invention relates to a screening method allowing the identification and selection of compounds targeting the transphosphorylase (also called phosphotransferase) domain of c-kit, more particularly compounds selected to be potent inhibitors of constitutively activated c-kit, while being unable to inhibit other activation pathways as for example the pathways leading to death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: June 1, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Patrice Dubreuil, Olivier Hermine
  • 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
    Patent number: 7718676
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles of formula I that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: May 18, 2010
    Assignees: AB Science, Centre National de la Recherche Scientifique (CNRS), Institut Curie
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20100121063
    Abstract: The present invention relates to an industrial process of preparing pharmaceutical compounds having the formula (1) which are useful as certain tyrosine kinase inhibitors and more particularly as c-kit and bcr-abl inhibitors. The groups R1 and R2, identical or different, represent each a hydrogen, halogen atom, an alkyl, an alkoxy, a trifluoromethyl, an amino, an alkylamino, a dialkylamino, a solubilising group; m is 0-5 and n is 0-4; the group R3 represents an aryl or an heteroaryl group as described in claims herein.
    Type: Application
    Filed: February 13, 2008
    Publication date: May 13, 2010
    Applicant: AB SCIENCE
    Inventors: Alain Moussy, Philippe Reginault, Francois Bellamy, Anne Lermet
  • 2-Aminoaryloxazole compounds as tyrosine kinase inhibitors
    Publication number: 20100113471
    Abstract: The present invention relates to novel compounds selected from 2-aminoaryloxazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl, FGFR3 and/or Flt-3 inhibitors.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Inventors: Alain Moussy, Camille Wermuth, David Grierson, Abdellah Benjahad, Martine Croisy, Marco Ciufolini, Bruno Giethlen
  • Use of tyrosine kinase inhibitors for treating allergic diseases
    Patent number: 7700610
    Abstract: The present invention relates to a method for treating allergic diseases such as asthma, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: April 20, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS
    Publication number: 20100093750
    Abstract: The present invention relates to a method for treating solid cancers including non-small 5 cell lung cancer, pancreatic, bladder, breast and ovarian cancer as well as advanced biliary tract cancers comprising administering at least one antineoplasticagent such as a nucleotide analog, for example gemcitabine, or an antimitotic such as docetaxel, in combination with a tyrosine kinase inhibitor selected from 2-aminoarylthiazoles and 2-aminoaryloxazoles.
    Type: Application
    Filed: January 11, 2008
    Publication date: April 15, 2010
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
    Patent number: 7678805
    Abstract: The present invention relates to a method for treating inflammatory bowel diseases (IBD), such as crohn's disease, comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: March 16, 2010
    Assignee: AB Science
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use of tyrosine kinase inhibitors for treating CNS disorders
    Publication number: 20090082360
    Abstract: The present invention relates to a method for treating CNS disorders, more particularly selected from the group consisting of depression, schizophrenia, anxiety, migraine, memory loss, pain and neurodegenerative diseases, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Application
    Filed: August 13, 2008
    Publication date: March 26, 2009
    Applicant: AB SCIENCE
    Inventors: Alain MOUSSY, Jean-Pierre Kinet
  • 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS
    Publication number: 20080255141
    Abstract: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferation metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: July 18, 2007
    Publication date: October 16, 2008
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
  • Substituted Oxazole Derivatives and their Use as Tyrosine Kinase Inhibitors
    Publication number: 20080242704
    Abstract: The present invention relates to novel compounds selected from substituted oxazole derivatives of formula (I) that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit, bcr-abl and Fit-3 inhibitors.
    Type: Application
    Filed: April 4, 2006
    Publication date: October 2, 2008
    Inventors: David Grierson, Abdellah Benjahad, Alain Moussy, Martine Croisy
  • 2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases
    Patent number: 7423055
    Abstract: The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: September 9, 2008
    Assignee: AB Science
    Inventors: Marco Ciufolini, Camille Wermuth, Bruno Gielthen, Alain Moussy
  • Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
    Publication number: 20080207572
    Abstract: The present invention relates to a method for treating Multiple Myeloma (MM), FGFR3+ myeloma, especially relapsed or refractory multiple myeloma (4/14) expressing FGFR3, comprising administering a dual C-KIT/FGFR3 inhibitor, such as 2-aminoarylthiazoles and 2-aminoaryloxazoles.
    Type: Application
    Filed: July 13, 2006
    Publication date: August 28, 2008
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy
    Publication number: 20080146585
    Abstract: The present invention relates to a method for treating inflammatory muscle disorders including myositis and muscular dystrophy comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cell degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Application
    Filed: April 19, 2005
    Publication date: June 19, 2008
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • 2-(3-Substituted-Aryl) Amino-4-Aryl-Thiazoles As Tyrosine Kinase Inhibitors
    Publication number: 20080039466
    Abstract: The present invention relates to novel compounds selected from 2-(3substitutedaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
    Type: Application
    Filed: January 28, 2005
    Publication date: February 14, 2008
    Inventors: Alain Moussy, Marco Ciufolini, Camille Wermuth, Bruno Giethlen
  • Tailored Treatment Suitable for Different Forms of Mastocytosis
    Publication number: 20080025916
    Abstract: The present invention relates to a method for a tailored treatment of mastocytosis comprising a) assessing whether or not a c-kit mutation at position 816 is detected in a sample of a patient and b) administering a specific 816 mutant c-kit inhibitor in case a mutation is detected in step a) or an inhibitor displaying efficacy on c-kit wild in case no mutation is detected in step a). The invention is more particularly suited 10 for treating category II, III and IV mastocytosis.
    Type: Application
    Filed: February 27, 2004
    Publication date: January 31, 2008
    Inventors: Jean-Pierre Kinet, Alain Moussy
  • Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases
    Publication number: 20080004279
    Abstract: The present invention relates to a method for treating plasmodium related diseases comprising administering a compound capable of inhibiting tyrosine kinases, to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors including c-kit inhibitors and more particularly non-toxic, selective and potent tyrosine kinases inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Application
    Filed: April 19, 2005
    Publication date: January 3, 2008
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons
    Publication number: 20070249628
    Abstract: The present invention relates to a method for treating patients exposed to chemical or biological weapons comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Application
    Filed: April 19, 2005
    Publication date: October 25, 2007
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use of C-Kit Inhibitors for Treating Fibrosis
    Publication number: 20070225293
    Abstract: The present invention relates to a method for treating fibrosis and related disorders comprising administering a compound capable of depleting mast cell or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Application
    Filed: April 19, 2005
    Publication date: September 27, 2007
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Use of tyrosine kinase inhibitors for treating cerebral ischemia
    Publication number: 20070191267
    Abstract: The present invention relates to a method for treating cerebral ischemia, comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation to a human in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.
    Type: Application
    Filed: April 28, 2004
    Publication date: August 16, 2007
    Inventors: Jean-Pierre Kinet, Alain Moussy